Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 15/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | STAT1 | P42224 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23389863 | 0.87 | LRRK2 (0.38) | LRRK2TGFBR1MAPK14TGFBR2NPC1 | |
| SCHEMBL25822668 | 0.87 | BTK (0.40) | TGFBR1 | |
| SCHEMBL29967458 | 0.87 | BTK (0.40) | TGFBR1 | |
| SCHEMBL23392193 | 0.81 | TGFBR1 (0.40) | TGFBR1MAPK14 | |
| SCHEMBL29796526 | 0.81 | TGFBR1 (0.40) | TGFBR1MAPK14 | |
| SCHEMBL23418646 | 0.81 | LRRK2 (0.37) | LRRK2TGFBR1MAPK14TGFBR2NPC1 | |
| SCHEMBL29967907 | 0.81 | LRRK2 (0.37) | LRRK2TGFBR1MAPK14TGFBR2NPC1 | |
| SCHEMBL28785430 | 0.80 | TGFBR1 (0.41) | LRRK2TGFBR1MAPK14TGFBR2 | |
| SCHEMBL23408090 | 0.78 | TGFBR1 (0.42) | TGFBR1MAPK14 | |
| SCHEMBL25084936 | 0.75 | TGFBR1 (0.37) | LRRK2TGFBR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210154179-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| WO-2021102468-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154179-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | LRRK2 1645/4885TGFBR1 211/4885MAPK14 1504/4885 |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | LRRK2 1645/4885TGFBR1 211/4885MAPK14 1504/4885 |
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | LRRK2 1645/4885TGFBR1 211/4885MAPK14 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.